Bristol Myers Earnings Estimate

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Many public companies, such as Bristol Myers, manage the perception of their earnings on regular bases to make sure that analyst estimates are accurate. Future earnings calculations are essential input when attempting to value a firm. Bristol Myers is projected to generate 6.1667 in earnings per share on 31st of December 2020. Bristol Myers earnings estimates module stress-tests analyst consensus about projected Bristol Myers Squibb EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Trending Equities.

Search Earnings Estimates

Profit Margin is likely to grow to 0.14 in 2020, whereas Gross Profit is likely to drop slightly above 17.7 B in 2020.
Estimates (6)
LowProjected EPSHigh
LowEstimated ValueHigh
LowReal ValueHigh
12 Analysts
LowTarget PriceHigh

Bristol Myers Earnings Boundaries

Current EPS
10th of July 2020
Estimated EPS
Bristol Myers Earnings per Share projection breakdown
Calculation of earning per share of Bristol Myers Squibb is based on official Zacks consensus of 4 analysts regarding Bristol Myers future annual earnings. Given the historical accuracy of 90.47%, the future earnings per share of Bristol Myers is estimated to be 6.1667 with lowest and highest values of 6.08 and 6.2 respectively. Please note that this consensus of annual earnings estimates for Bristol Myers Squibb is an estimate of EPS before non-recurring items and including employee stock options expenses
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2020





Bristol Myers Earnings History

  Bristol Myers Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

Bristol Myers Accumulated Retained Earnings Deficit are fairly stable at the moment as compared to the past year. Bristol Myers reported Accumulated Retained Earnings Deficit of 34.47 Billion in 2019. Price to Earnings Ratio is likely to grow to 37.29 in 2020, whereas Earning Before Interest and Taxes EBIT is likely to drop slightly above 4.6 B in 2020. Weighted Average Shares Diluted is likely to grow to about 1.9 B in 2020, whereas Weighted Average Shares is likely to drop slightly above 1.6 B in 2020.

Bristol Myers Earnings per Share Projection vs Actual

Bristol Myers Estimated Earnings per Share

About Bristol Myers Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Bristol Myers earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Bristol Myers estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Bristol Myers fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.' Please read more on our stock advisor page.
Last ReportedProjected for 2020
Accumulated Retained Earnings Deficit34.5 B37 B
Earning Before Interest and Taxes EBITB4.6 B
Earnings per Basic Share 2.02  1.93 
Earnings per Diluted Share 2.01  1.92 
Price to Earnings Ratio 31.78  37.29 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA6.7 B5.8 B
Earnings before TaxB4.6 B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes hematology, oncology, cardiovascular, and immunology. The companys products include Opdivo, a biological product for anti-cancer indications Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, and Ubiquigent Limited clinical collaboration agreement with NeoImmuneTech, Inc. and partnership with Astrazeneca Plc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page